The trial will see healthy volunteers infected with dengue to test the impact of AbViro’s monoclonal antibody therapy.
Island noted that high-level results from the phase 2b studies were anticipated in the next six to eight weeks. Dengue fever ...
Island Pharmaceuticals has completed subject dosing for the phase 2b therapeutic arm of its phase 2a/b PROTECT clinical trial of ISLA-101 in dengue fever. Island Pharmaceuticals Ltd (ASX:ILA)said ...
The Quezon City government declared a dengue outbreak on Saturday amid the steep rise in the number of residents contracting ...
If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and ...